NYVAC-HIV-PT1

BIOLOGICAL2 trials

Sponsors

HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV Infections

Phase 1

Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults

CompletedNCT01799954

HIV Vaccine Trials NetworkHIV Infections

Start: 2012-08-31End: 2014-12-31Updated: 2015-03-25

Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults

WithdrawnNCT01964937

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2014-04-30Updated: 2021-10-15

Related Papers

A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials

Emerging Microbes & Infections2025-04-071 citations

The Question of HIV Vaccine: Why Is a Solution Not Yet Available?

Journal of Immunology Research2024-01-0112 citations

Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial.

2019-10-0738 citations

Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials.

2017-01-2510 citations